Lutzomyia longipalpis, 15 other species of the genus Lutzomyia, and one species of Brumptomyia were collected in an endemic focus of cutaneous leishmaniasis in a river canyon 450 m above sea-level, in Rio Claro, Antioquia, Colombia. The presence of Lu. longipalpis is associated with the destruction of the primary forest and the development of new farmland and rural settlement in this region. Th...

The aims of the study were to determine the blood feeding preferences of sandflies and to identify species of Leishmania that infected phlebotomines in Caxias, Maranhão, Brazil, an area that is highly endemic for leishmaniasis. Sandflies were captured in light traps located in the peridomiciliary environments of randomly selected houses in urban and rural settings between 1800 and 0600 hours on...

ì Thiti?| @ | iLh) uLh | i }hL | _)?@4 Ut Lu | i L̀h*_ ` _i ìM | @| |@!it ?|L @UUL ?| | i _i h@?}i Lu t|LU @t| U }hL | h@|it ? | i ? 4Mih Lu T@}it Tih t |ic @t i** @t | i u@U| | @| ?i t |it @hi Uhi@|i_ @| _ gihi?| | 4it A t *i@_t |L | i Thi_ U| L? Lu @ ? iht@* TL ih *@ ? | i _ t|h M | L? Lu | i ? 4Mih Lu T@}it Tih t |i U i UL?€h4 i Tih 4i?|@**) M) @?@*)3 ?} _@|@ uhL4 *@h}i Uh@ *t 4@_i M) | i ti@...

Introduction:Targeted radionuclide therapy (TRT) has been demonstrated to be an effective therapeutic tool in patients with disseminated bone metastasis. TRT is generally performed with a single radionuclide. In this study we investigated the feasibility of combined TRT with a high-energy beta emitter (153Sm) and a low energy beta emitter (177Lu) in wistar...

American cutaneous leishmaniasis (ACL) is endemic in the State of Rio Grande do Sul, Brazil. As reports of nearby hospitals suggest, the Parque Estadual do Turvo seems to serve as a source for the disease. During three months from November 1996 to February 1997 we collected, in this park, 2,228 sandflies (10 Lutzomyia species and 2 6species). We applied the polymerase chain reaction to 920 fema...

The biodistribution of the anti-CD37 radioimmunoconjugate (177)Lu-tetraxetan-tetulomab ((177)Lu-DOTA-HH1) was evaluated. Biodistribution of (177)Lu-tetraxetan-tetulomab was compared with (177)Lu-tetraxetan-rituximab and free (177)Lu in nude mice implanted with Daudi lymphoma xenografts. The data showed that (177)Lu-tetulomab had a relevant stability and tumor targeting properties in the human l...